Top Page
Indivior
(LSE:INDV)
Indivior (INDV) vs. S&P 500 (SPY)
Indivior Business Overview & Revenue Model
Indivior Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.19B | 1.09B | 901.00M | 791.00M | 647.00M |
| Gross Profit | ||||
| 957.00M | 907.00M | 742.00M | 664.00M | 550.00M |
| EBIT | ||||
| 32.00M | -4.00M | -91.00M | 213.00M | -156.00M |
| EBITDA | ||||
| 84.00M | 66.00M | -45.00M | 238.00M | -123.00M |
| Net Income Common Stockholders | ||||
| 2.00M | 2.00M | -53.00M | 205.00M | -148.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 320.00M | 410.00M | 893.00M | 1.10B | 858.00M |
| Total Assets | ||||
| 1.32B | 1.95B | 1.77B | 1.83B | 1.53B |
| Total Debt | ||||
| 375.00M | 282.00M | 277.00M | 286.00M | 285.00M |
| Net Debt | ||||
| 56.00M | -34.00M | -497.00M | -816.00M | -573.00M |
| Total Liabilities | ||||
| 1.67B | 1.97B | 1.72B | 1.63B | 1.45B |
| Stockholders Equity | ||||
| -348.00M | -11.00M | 51.00M | 203.00M | 82.00M |
| Cash Flow | Free Cash Flow | |||
| 5.00M | -368.00M | -10.00M | 319.00M | -197.00M |
| Operating Cash Flow | ||||
| 36.00M | -315.00M | -4.00M | 353.00M | -193.00M |
| Investing Cash Flow | ||||
| 69.00M | -98.00M | -223.00M | -14.00M | -4.00M |
| Financing Cash Flow | ||||
| -102.00M | -46.00M | -100.00M | -94.00M | -10.00M |
Indivior Technical Analysis
Indivior Risk Analysis
Indivior Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £173.61B | 31.62 | 17.43% | 2.19% | 14.82% | 14.98% | |
68 Neutral | £60.01B | 23.53 | 19.06% | 4.13% | 3.46% | -48.06% | |
64 Neutral | $44.93B | 16.09 | 35.82% | 3.81% | -3.88% | -11.33% | |
61 Neutral | £7.30B | 31.26 | 17.17% | 4.83% | 5.38% | 86.34% | |
54 Neutral | £943.47M | ― | ― | 5.76% | -729.39% | ||
49 Neutral | $6.86B | 0.72 | -52.93% | 2.49% | 20.83% | 1.11% |
Indivior Earnings Call Summary
Indivior Corporate Events
Indivior PLC, a UK-based company, has announced a change in its major holdings due to an acquisition or disposal of voting rights and financial instruments by Millennium International Management LP. This change resulted in a decrease in the total percentage of voting rights held by Millennium from 5.146% to 4.925%, indicating a slight reduction in their influence over Indivior’s decision-making processes.
Indivior PLC has announced the publication of its Notice of the 2025 Annual General Meeting (AGM) on its website. The meeting is scheduled for May 8, 2025, in London. The company has also submitted necessary documents to the UK Financial Conduct Authority for inspection, including proposed amendments to its Articles of Association and a letter on the Directors’ Remuneration Policy. This announcement is part of Indivior’s compliance with regulatory requirements and provides shareholders with important information regarding governance and policy changes.
Indivior PLC, a UK-based company, has announced a change in its major holdings as Rubric Capital Management LP, a US-based entity, has increased its voting rights in the company. The acquisition or disposal of voting rights and financial instruments by Rubric Capital Management LP has led to a new total of 6.27% voting rights in Indivior, up from the previous 5.12%. This change in holdings could impact Indivior’s strategic decisions and influence its market positioning.
Indivior PLC has announced changes in the share interests of its Chief Executive Officer, Mark Crossley, and Chief Financial Officer, Ryan Preblick, as part of the Deferred Bonus Plan 2018. The awards granted in 2023 have vested, resulting in the delivery of shares to both executives. This notification aligns with the UK Market Abuse Regulation, reflecting the company’s adherence to regulatory requirements.
Indivior PLC has released its 2024 Annual Report and Accounts, which are now available on its website. The report will also be submitted to the UK Financial Conduct Authority’s National Storage Mechanism for public inspection. Shareholders who have opted for paper communications will receive hard copies of the report and the Notice of Annual General Meeting 2025 by March 27, 2025. This publication is in compliance with the FCA’s Disclosure Guidance and Transparency Rules.
Indivior PLC has announced a change in the interests of its Chief Executive Officer, Mark Crossley, involving a Conditional Award of 9,375 Ordinary Shares under the Indivior Deferred Bonus Plan 2018. This award is part of the deferral of 25% of the gross bonus earned under the Indivior 2024 Annual Incentive Plan, set to vest on the second anniversary of the award date, contingent upon continued employment. This notification complies with the UK Market Abuse Regulation, reflecting the company’s adherence to regulatory requirements and its commitment to transparent executive compensation practices.
Indivior PLC, a UK-based company, has announced a change in its major holdings. Madison Avenue Partners LP, based in New York, has increased its voting rights in Indivior to 5.185508% from a previous 4.053609%. This acquisition of voting rights signifies a stronger influence of Madison Avenue Partners in the decision-making processes of Indivior, potentially impacting its strategic direction and stakeholder interests.
Indivior PLC announced changes to the share interests of its CEO, Mark Crossley, following the release of awards under the Long-Term Incentive Plan. The awards, granted in 2020 and vested in 2023, were released in March 2025, resulting in Crossley holding 340,953 shares in the company. This transaction aligns with the UK Market Abuse Regulation, reflecting Indivior’s commitment to transparency and regulatory compliance.
Indivior PLC announced that Dr. Keith Humphreys, a Non-Executive Director, acquired 1,500 ordinary shares of the company at an average price of $9.149 per share, increasing his total shareholding to 3,879 shares. This transaction, conducted on the Nasdaq Global Select Market, reflects ongoing confidence in the company’s market position and strategic direction, potentially influencing stakeholder perceptions positively.
Indivior PLC has announced the granting of Conditional Awards over Ordinary Shares under its 2024 Long-Term Incentive Plan to key managerial personnel. The vesting of these awards is contingent upon continued employment and the achievement of specific performance conditions, including relative Total Shareholder Return and market growth metrics. This move is part of Indivior’s strategy to align the interests of its leadership with company performance, potentially impacting its operational focus and market positioning.
Indivior PLC announced that Vishal Kalia, Chief Strategy and Operating Officer, purchased 2,262 ordinary shares at an average price of $8.87 per share, and Nisha Jairath, associated with Kalia, acquired 1,261 shares at £7.01 each. These transactions, conducted on February 28, 2025, reflect a significant personal investment by a key executive and associated person, potentially indicating confidence in the company’s future performance.
Indivior PLC, a UK-based company, has announced a change in its major holdings due to an acquisition or disposal of voting rights and financial instruments by Rubric Capital Management LP. The notification indicates that Rubric Capital Management LP now holds a total of 5.12% of voting rights in Indivior, with 1.27% attached to shares and 3.85% through financial instruments. This change in holdings could potentially impact Indivior’s shareholder dynamics and influence its strategic decisions.
Indivior PLC, a UK-based company, has announced a change in its shareholder structure. Madison Avenue Partners LP, a New York-based investment firm, has increased its voting rights in Indivior PLC to 4.05% from a previous 3.18%. This acquisition of voting rights reflects a strategic move by Madison Avenue Partners, potentially impacting Indivior’s governance and decision-making processes.
Indivior PLC announced the vesting of conditional awards under its Long-Term Incentive Plan for key managerial personnel, resulting in the delivery of shares to Company Secretary Kathryn Hudson and Chief Strategy and Operating Officer Vishal Kalia. This transaction reflects the company’s ongoing commitment to rewarding its leadership, potentially impacting its internal stakeholder dynamics and reinforcing its market position.
Indivior PLC announced significant changes to its Board of Directors, including a reduction in board size to seven directors and the commencement of a search for a new Independent Non-Executive Director. These changes align with the company’s strategic shift to a US primary listing and are part of an amended agreement with Oaktree Capital Management. The company also announced leadership changes within its committees and the discontinuation of its Operational Committee, reflecting a strategic realignment to enhance its governance and operational focus.
Indivior PLC announced that as of March 1, 2025, its issued share capital consists of 124,655,858 Ordinary Shares, with no shares held in Treasury. This update is in compliance with the FCA’s Disclosure Guidance and Transparency Rule 5.6.1, and the total voting rights are 124,655,858. Shareholders can use this figure to determine their notification requirements under the FCA’s rules.
Indivior PLC announced that Daniel Ninivaggi, a Non-Executive Director, acquired 15,000 ordinary shares of the company at an average price of $8.78 per share. This transaction, conducted on February 27, 2025, on the Nasdaq Global Select Market, reflects a significant personal investment by a key member of the company’s board, potentially indicating confidence in the company’s future performance.
Indivior PLC announced a significant change in its shareholder structure as Morgan Stanley’s total applicable holding in the company dropped below the 5% threshold, triggering a notification obligation. As a result, Morgan Stanley applied the trading book exemption to its remaining applicable holding of 4.979353% as of February 25, 2025. This development may impact Indivior’s market perception and investor confidence, as changes in major holdings can influence stakeholder sentiment and the company’s strategic direction.
Indivior PLC announced that Robert Schriesheim, a Non-Executive Director, has acquired 58,833 ordinary shares at an average price of $8.5644 per share. This transaction increases Schriesheim’s total shareholding in the company to 80,233 shares, reflecting a significant personal investment and potential confidence in the company’s future performance.
Indivior PLC announced that Dr. David Wheadon, the Chair of the company, has acquired 10,000 ordinary shares at an average price of $8.4281 per share. This transaction highlights Dr. Wheadon’s confidence in the company’s future prospects and could have positive implications for stakeholder sentiment and the company’s market positioning.
Indivior PLC has announced the appointment of Joe Ciaffoni as the new Chief Executive Officer, succeeding Mark Crossley. Ciaffoni, with over 30 years of experience in the pharmaceutical and biotech industries, is expected to drive the next stage of growth for Indivior, a leader in addiction treatment. The transition is aimed at ensuring stability and continuity, with Ciaffoni’s leadership anticipated to enhance shareholder value and expand the company’s impact in the addiction treatment space.
Indivior PLC, a UK-based company, has announced a significant change in its voting rights structure due to Morgan Stanley’s acquisition of voting rights. Morgan Stanley now holds a total of 5.32% of Indivior’s voting rights, marking a notable shift in the company’s shareholder dynamics. This development could impact Indivior’s strategic decisions and influence its market positioning.
Indivior has announced that the FDA approved label changes for its SUBLOCADE® injection, a treatment for moderate to severe opioid use disorder (OUD). The changes include a rapid initiation protocol that reduces the time to treatment from one week to one hour, and alternative injection sites, enhancing flexibility and potentially improving patient adherence. These updates reflect Indivior’s commitment to patient-centered care and may streamline treatment, offering significant benefits for healthcare providers and patients seeking effective OUD management.
Indivior PLC reported a 9% increase in net revenue for FY 2024, driven by strong performance of SUBLOCADE, which saw a 20% rise in net revenue. The company is focusing on streamlining operations to save over $100 million annually, reinvesting in long-term growth and its OUD assets, despite facing competitive pressures in the U.S. market. For FY 2025, Indivior expects a modest decline in SUBLOCADE revenue and a significant overall revenue drop due to intensified generic competition for SUBOXONE Film and the discontinuation of PERSERIS marketing. Despite these challenges, Indivior remains optimistic about achieving profitable growth and delivering value to shareholders by focusing on its key strategic objectives.
Indivior announced a delay in the FDA’s final review of proposed label changes for its product SUBLOCADE, specifically for rapid initiation protocol and alternative injection sites. Although the FDA has accepted the proposed label with no outstanding issues, the delay may impact Indivior’s timeline for implementing these changes, potentially affecting its market strategy and stakeholder expectations.
Indivior PLC announced it will release its Q4 and full-year 2024 financial results on February 20, 2025. The company’s CEO, Mark Crossley, along with other leadership members, will present the results via a live webcast. This announcement provides stakeholders with an opportunity to gain insights into Indivior’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.
Indivior PLC has announced the repurchase and cancellation of 204,247 ordinary shares as part of its $100 million Share Repurchase Program. This action reduces the total number of shares in circulation to 124,137,286, which may affect shareholders’ notification obligations under financial regulations.
Indivior PLC has completed a share repurchase program initially announced in July 2024. The program, executed by Morgan Stanley & Co. International Plc, involved the purchase and cancellation of over 9.4 million shares at an average price of £8.2486, totaling nearly $100 million. This strategic move is likely to impact the company’s shareholder value positively by reducing the number of outstanding shares.
Indivior PLC has announced a total voting rights update as per the FCA’s Disclosure Guidance and Transparency Rule. As of February 1, 2025, the company has 124,137,286 ordinary shares in issue, with no shares held in treasury. This figure reflects the total voting rights, which shareholders can use to determine the need to notify changes in their interests as required by regulatory rules.
Indivior PLC has appointed Daniel A. Ninivaggi as an Independent Non-Executive Director to its Board, effective January 31, 2025. Ninivaggi brings extensive public company experience and expertise in operations, capital allocation, and legal and finance, which is expected to enhance Indivior’s mission to transform the lives of patients struggling with opioid use disorder. This strategic leadership change is anticipated to strengthen Indivior’s position as a global leader in OUD treatments, benefiting stakeholders and supporting the company’s continued growth.
Indivior PLC has appointed Dr. David Wheadon as the new Chair of its Board, effective immediately. Dr. Wheadon brings extensive experience from previous roles at AstraZeneca and other major pharmaceutical organizations. His appointment signals the company’s ongoing commitment to leveraging strong leadership to continue its mission of pioneering treatments for opioid use disorder and delivering value to shareholders and stakeholders. The Board also plans to appoint an additional Non-Executive Director soon, indicating strategic moves to strengthen governance and operational oversight.
Indivior PLC, a UK-based company, has announced that Morgan Stanley’s voting rights in the company have fallen below the 5% threshold, triggering a notification. This change resulted from Morgan Stanley’s application of the trading book exemption, leaving them with a 4.96% stake in Indivior as of January 23, 2025. The notification indicates a shift in Morgan Stanley’s holdings, which could impact the company’s market dynamics and investor considerations.
Indivior PLC has executed a share repurchase program, purchasing and canceling 171,590 ordinary shares over a recent period, affecting its share count and capitalization structure. This move, carried out through Morgan Stanley, is part of a $100 million program and provides shareholders with updated information for regulatory compliance under the FCA’s rules.
Indivior PLC is undertaking a share repurchase program, having repurchased 171,590 ordinary shares for cancellation between January 20 and January 24, 2025, as part of its $100 million initiative. This move results in Indivior having 124,268,559 ordinary shares with voting rights remaining in issue, which can impact shareholder notifications under FCA rules.
Indivior PLC, a UK-based company, has reported a significant change in its voting rights structure due to an acquisition of shares by Morgan Stanley. The notification reveals Morgan Stanley now holds a total of 5.10% of voting rights in Indivior PLC, marking a substantial increase from its previous position of no voting rights. This change could potentially influence Indivior’s decision-making process and reflects a strategic move by Morgan Stanley to increase its influence in the company.
Indivior PLC has announced the repurchase and cancellation of 222,704 of its ordinary shares as part of its $100 million Share Repurchase Program. This strategic move reduces the total number of shares in circulation to 124,440,149, which may affect shareholders’ notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. The repurchase is expected to enhance shareholder value and reflects the company’s commitment to optimizing its capital structure.
Indivior PLC announced a correction to a previous announcement regarding its Share Repurchase Program. The company clarified the start date for the repurchase of shares, stating it began on January 6, 2025, instead of 2024. As part of this program, Indivior completed the purchase of 194,876 ordinary shares, bringing its total to 124,633,727 shares with voting rights. This transaction is expected to impact shareholder calculations in accordance with FCA’s rules.
Indivior PLC announced the repurchase and cancellation of 194,876 ordinary shares as part of its $100 million Share Repurchase Program. Following this transaction, the company has 124,633,727 ordinary shares with voting rights in issue, serving as a crucial reference for shareholders under the FCA’s Disclosure Guidance and Transparency Rules.
Indivior has announced its transition to a US primary listing by providing historical financial information in US GAAP and certain reconciliations to IFRS. This move is expected to enhance US analyst and investor interest and is necessary for inclusion in major US equity indices. The transition follows shareholder approval in May 2024, and the company plans to release FY 2025 guidance on a US GAAP basis. With this shift, Indivior aims to strengthen its market position in the US and align itself with major financial reporting standards.
Indivior PLC, a UK-based company, announced that Madison Avenue Partners LP, a New York-based investment firm, has increased its voting rights in the company to 3.181194%. This acquisition reflects a significant change from the previous position of 1.151633%. The increase in voting rights may influence Indivior’s future strategic decisions and highlights Madison Avenue Partners’ growing interest in the company, which could impact stakeholders and market dynamics.
Indivior PLC has announced its total voting rights and capital, stating that as of January 1, 2025, the company’s issued share capital comprised 124,903,607 ordinary shares with no shares held in treasury. This update is significant for shareholders as it provides the denominator necessary for calculating their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
Indivior PLC has been notified of a change in major holdings involving Two Seas Capital LP, which has adjusted its voting rights in the company. As of December 27, 2024, Two Seas Capital LP holds 9.960998% of voting rights, a slight decrease from its previous position. This adjustment may impact Indivior’s shareholder dynamics and influence, reflecting changes in strategic investments by major stakeholders.
Indivior PLC announced the purchase and cancellation of 92,950 of its ordinary shares as part of its $100 million Share Repurchase Program. This move reduces the total number of shares in circulation, potentially increasing the value of remaining shares, and indicates the company’s strategy to enhance shareholder value.